A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib
Status:
Withdrawn
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of crizotinib combined with
CHOP chemotherapy for patients with ALK(+) Systemic Anaplastic Large Cell Lymphoma.
Phase:
Phase 4
Details
Lead Sponsor:
Jun Zhu
Collaborators:
Air Force General Hospital of the PLA Anhui Provincial Hospital Beijing Hospital Cancer Institute and Hospital, Chinese Academy of Medical Sciences Chinese PLA General Hospital First Hospitals affiliated to the China PLA General Hospital Peking Union Medical College Hospital Peking University First Hospital Peking University People's Hospital Peking University Third Hospital Zhejiang University